- Oxford University and AstraZeneca are developing COVID-19 vaccine AZD1222
- Phase 3 trials of AZD1222 were halted as a volunteer got ill
- AZD1222 will be manufactured in India as Covishield
New Delhi: Hours after clinical trials for AstraZeneca and Oxford University coronavirus vaccine resumed on Saturday in the UK, pharma major Serum Institute of India (SII) said it will resume the trials in India once Drugs Controller General of India (DCGI) gives it requisite permission. AstraZeneca PLC had on September 6 paused the trial of coronavirus vaccine (recombinant) as a volunteer developed an unexplained illness. It was also reported that the clinical trials had been put on hold in other countries including USA, UK, Brazil and South Africa.
Following the developments, India’s top drugs regulator had asked SII to suspend any new recruitment in phase two and three clinical trials for COVID-9 vaccine till further orders.
The DCGI directed the pharma company to increase safety monitoring of the subjects already vaccinated with the candidate vaccine and submit its plan and report.
SII now has to submit clearance from Data and Safety Monitoring Board (DSMB), UK and DSMB India to obtain clearance from DCGI’s office before it can resume trials, officials said.
Once DCGI will give us the permission to restart the trials in India, we will resume the trials, Serum Institute of India said in its statement.
According to the reports on Saturday, clinical trials for AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
The company said that that the “standard review process triggered a voluntary pause” to all global trials on September 6 so that independent committees and internal regulators could review the safety data.
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so. The company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic, Astra Zeneca said in a statement.
Adar Poonawalla, CEO and Owner, Serum Institute of India, said no conclusions should be drawn till the trials are completed.
As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chains of events are a clear example why we should not bias the process and should respect the process till the end. Good news, UniofOxford, he said in a tweet.
India’s top drugs regulator granted permission to SII on August 2 to conduct phase II/III clinical trial of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) at various clinical trial sites in the country to determine its safety and immunogenicity.
The vaccine will be manufactured by Serum Institute in India under technical collaboration with Oxford University and AstraZeneca which have developed the candidate vaccine.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.